New Kidney Treatments Offer Hope for Reversal and Prevention
- 6 hours ago
- 2 min read
Recent scientific advancements are challenging the long-held assumption that kidney damage is a progressive and irreversible condition, signaling a potential transformation in how kidney disease is managed worldwide. Three distinct areas of research—gene therapy, ceramide control, and stem cell application—are offering promising pathways toward restoring function, preventing failure, and improving treatment efficacy.
For individuals with type 1 diabetes, a serious and common complication is diabetic kidney disease, which affects one in three people and often goes undetected until severe. Traditional treatments currently focus only on slowing the damage. However, a new approach developed by the University of Bristol utilized gene therapy to target the root cause of the damage: the tiny filter called the glomerulus. Researchers delivered a protein called VEGF-C directly into the kidney cells of diabetic mice using a harmless virus. This approach not only improved kidney function but also resulted in a remarkable 64% reduction in albuminuria—a common indicator of kidney disease. This reduction is more than twice what the American Diabetes Association recommends to slow the progression of chronic kidney disease. This novel gene therapy offers a long-term potential solution where no specific protective drugs currently exist.
Separately, other researchers have identified a potential strategy for reversing acute kidney damage by targeting ceramides, a type of fat molecule linked to cellular injury. High ceramide levels interfere with mitochondrial function, leading to cell death, inflammation, and loss of kidney function. In animal trials, blocking ceramide production protected kidney cells completely and allowed renal function to return to normal. This suggests a new therapeutic focus on preserving cellular energy systems before permanent damage sets in, potentially reducing reliance on dialysis or transplantation following sudden injury.
Finally, for the more than four million people globally facing end-stage kidney disease (ESKD) that requires hemodialysis, researchers are improving the durability of necessary surgical accesses. Patients typically receive an arteriovenous fistula (AVF) to facilitate dialysis, but these accesses fail about 60% of the time due to vein narrowing. Mayo Clinic researchers found that transplanting a patient's own mesenchymal stem cells—derived from fat—into the vein before AVF surgery helped prevent the inflammation and vein narrowing. These stem cells secrete healing growth factors and have anti-inflammatory properties. In early clinical trials, AVFs healed faster and were more durable in most participants who received the stem cells, offering potential to extend the time patients can use dialysis before needing a transplant.
While these results are highly promising—challenging years of assumptions in nephrology—scientists stress that they are still in early stages, mostly tested in animal models, and require extensive clinical trials to confirm safety and effectiveness in humans.
🔖 Sources
Keywords: New kidney treatments
New kidney treatments
Comments